Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...

BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $105.00 price target. This confirmation followed the U.S. Food and Drug ...

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The trial tested amycretin in its injectable form, but Novo Nordisk is also separately developing the drug in pill form. Investors cheered an early trial of the pill early last year that showed weight ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

For example, he proposed 25% tariffs on imports from Canada and Mexico ... prices due to tariffs are passed along to consumers. Novo Nordisk's type 2 diabetes drug, Ozempic, is the main ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...